Aurobindo Pharma’s Subsidiary Company CuraTeQ Biologics Gets UK Nod for Bevqolva

CuraTeQ Biologics, a step-down subsidiary of Aurobindo Pharma, has obtained marketing approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for Bevqolva, its biosimilar to bevacizumab.

Bevqolva Details

Bevqolva is a 25 mg/mL concentrate for infusion, available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials. It is administered via infusion into veins and is used to treat cancers such as:

• Metastatic colorectal cancer
• Non-squamous, non-small cell lung cancer
• Advanced/metastatic renal cell carcinoma
• Cervical cancer
• Fallopian tube, epithelial ovarian, and primary peritoneal cancer

About CuraTeQ Biologics

Based in Hyderabad, India, CuraTeQ Biologics focuses on creating affordable biosimilars for cancer and autoimmune diseases. Its pipeline includes 14 biosimilars with full end-to-end manufacturing capabilities.

About Aurobindo Pharma

Aurobindo Pharma, a global pharmaceutical leader, operates in over 150 countries with 29 regulatory-approved facilities. It offers a wide range of generic and speciality medicines across key therapeutic areas, supported by a robust R&D framework.

Aurobindo Pharma share price is trading at ₹1,245.15, marking an increase of ₹3.45 or 0.28% as of 9:58 am on December 23. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.